mRNA疫苗接种减轻动物模型中的病理性视网膜脉络膜新生血管
视网膜脉络膜新生血管(NV)可致视力损害与失明,现有抗血管生成药物需反复眼内注射且部分患者无应答。本研究以病理性新生血管特异表达的富含亮氨酸α-2-糖蛋白1(LRG1)为靶点,在小鼠中诱导抗LRG1抗体应答;激光诱导NV模型中LRG1 mRNA疫苗减小NV面积与渗漏并抑制小胶质细胞浸润,组织学分析显示对视网膜结构和胶质细胞活化无不良影响;Vldlr敲除小鼠中LRG1 mRNA给药抑制持续新生血管并下调关键血管生成介质。
要点
- LRG1 mRNA疫苗在小鼠中诱导抗LRG1抗体应答。
- 激光诱导NV模型中疫苗减小NV面积与渗漏并抑制小胶质细胞浸润。
- Vldlr敲除小鼠中LRG1 mRNA给药抑制持续新生血管并下调血管生成介质。
核心结论
- LRG1 mRNA疫苗可减轻动物模型中的病理性视网膜脉络膜新生血管,作者认为LRG1 mRNA作为CNV相关疾病的新策略具有治疗潜力。
研究设计与样本
- 动物实验研究:以LRG1为靶点的mRNA疫苗在小鼠中诱导抗LRG1抗体应答,并在激光诱导NV模型和Vldlr敲除小鼠中评估。
主要发现
- 激光诱导NV模型中,LRG1 mRNA疫苗减小NV面积与渗漏,同时抑制小胶质细胞浸润。
- 组织学分析显示疫苗对视网膜结构或胶质细胞活化无不良影响。
- Vldlr敲除小鼠中,LRG1 mRNA给药抑制持续新生血管并下调关键血管生成介质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Retinochoroidal neovascularization (NV), involved in macular degeneration, diabetic retinopathy, and other ocular diseases, causes vision impairment and blindness. Current treatments rely on repeated intraocular injections of anti-angiogenic drugs, which are burdensome for patients and clinicians, and some patients fail to respond to the treatments. This study investigates the potential of mRNA vaccination to mitigate NV and treat ocular pathologies. The vaccine targets leucine-rich alpha-2-glycoprotein 1 (LRG1), a protein specifically expressed in pathological neovascularization, inducing anti-LRG1 antibody responses in mice. In a laser-induced NV model, the LRG1 mRNA vaccine reduces NV area and leakage while inhibiting microglial cell infiltration. Histological analysis shows no adverse effects on retinal architecture or glial cell activation. Additionally, in Vldlr knockout mice, LRG1 mRNA administration suppresses ongoing neovascularization and downregulates key angiogenic mediators. These findings highlight the therapeutic potential of LRG1 mRNA as a novel strategy for CNV-associated diseases.
引用
- Yanagi Y, Ichikawa H, Nguyen LBT, et al. mRNA vaccination mitigates pathological retinochoroidal neovascularization in animal models. Vaccine. 2025. PMID: 40609263. doi:10.1016/j.vaccine.2025.127451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。